BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 22264132)

  • 1. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
    Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
    Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
    Ito K; Kusuhara H; Sugiyama Y
    Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.
    Takano J; Maeda K; Bolger MB; Sugiyama Y
    Drug Metab Dispos; 2016 Nov; 44(11):1808-1818. PubMed ID: 27538919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
    Tachibana T; Kato M; Sugiyama Y
    Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
    Sun X; Tang S; Hou B; Duan Z; Liu Z; Li Y; He S; Wang Q; Chang Q
    BMC Gastroenterol; 2021 Jan; 21(1):2. PubMed ID: 33407159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics.
    Kaddoumi A; Fleisher D; Heimbach T; Li LY; Cole S
    J Pharm Sci; 2006 Feb; 95(2):435-45. PubMed ID: 16381015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.
    Feick D; Rüdesheim S; Marok FZ; Selzer D; Loer HLH; Teutonico D; Frechen S; van der Lee M; Moes DJAR; Swen JJ; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1143-1156. PubMed ID: 37165978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits.
    Fang HM; Xu JM; Mei Q; Diao L; Chen ML; Jin J; Xu XH
    Acta Pharmacol Sin; 2009 Nov; 30(11):1566-72. PubMed ID: 19820718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
    Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
    J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
    Mudra DR; Desino KE; Desai PV
    Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.
    Kadono K; Akabane T; Tabata K; Gato K; Terashita S; Teramura T
    Drug Metab Dispos; 2010 Jul; 38(7):1230-7. PubMed ID: 20354105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.